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INTRODUCTION 
Chronic hepatitis B (CHB) is a major health problem worldwide. 
It is estimated that approximately 400 million people are infected 
with hepatitis B virus (HBV) globally.1 CHB can progress to cirrho-
sis, decompensated cirrhosis, hepatocellular carcinoma (HCC), and 
death.2 Korea is an HBV endemic area;2 therefore, CHB is a major 
public health problem in Korea. Several nucleos(t)ide analogues 
(NAs) have been developed over the past decade, and administra-
tion of NAs has played a crucial role in the treatment of CHB. In 
addition to lamivudine, there are currently four oral NAs available 
for CHB treatment, including adefovir dipivoxil, entecavir, telbi-
vudine, and tenofovir, which have shown greater antiviral activity 
compared with a placebo or lamivudine in patients with CHB.3-9 
Telbivudine (ß-L-2’-deoxythymidine) is a new synthetic nucleo-
side analogue and is a bioavailable L-nucleoside with specific anti-
HBV activity in vitro.10 Since telbivudine came on the market in 
October 2006, a new option has been given to clinicians to treat 
CHB patients, especially based on the results of the GLOBE trial.11 
The GLOBE trial showed that telbivudine has more potent anti-
viral activity and less viral resistance compared with lamivudine.11 
In the preclinical toxicological tests, telbivudine had no mutagenic 
or carcinogenic effects.12 A minority of telbivudine-treated patients 
experienced creatine kinase (CK) elevation, usually transient, and 
myopathy occurred rarely.10 However, in our recent clinical prac-
tice, we experienced myopathy with serum CK level elevation, 
which seemed to be associated with telbivudine in two patients 
who were siblings. Myopathy is characterized by muscle pain, 
weakness and moderately elevated CK levels.13 We report here the 
two cases of telbivudine-induced myopathy in patients with CHB 
to consider the adverse reaction mechanisms of telbivudine. 
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A 28-year-old man who received telbivudine therapy for chronic 
hepatitis B presented with progressive weakness of both lower 
legs and difficulty in ascending stairs over the past 4 months. And 
also, he was unable to lift up a dumbbell and do pushups due to 
weakness in both arm. He was diagnosed with CHB 3 years ago 
and started taking 600 mg of telbivudine once daily for 9 months 
to control HBV activation. Since taking telbivudine, the serum viral 
DNA level gradually decreased from 100,000 IU/mL to 222 IU/
mL, and the serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels were also normalized. However, 
he showed muscle weakness since taking telbivudine. Although 
there was no symptoms such as dysphagia, cramps, or sensory ab-
normality, the patient suffered from progressive and generalized 
weakness, especially of his legs, and had difficulty climbing stairs. 
He exhibited motor weakness (grade 4) of the hip flexor, making 
it difficult for him to stand up from the sitting position, but there 
was no sign of abnormal deep tendon reflex, muscle atrophy, or 
hypertrophy on physical examination. He had not taken any other 
medications that would be regarded as a cause of his symptoms 
while taking telbivudine. Laboratory examinations showed AST of 
59 IU/L, ALT of 26 IU/L, total bilirubin of 0.9 mg/dL, blood urea 
nitrogen (BUN) of 15.4 mg/dL, and serum creatinine of 0.7 mg/
dL. His serum CK level was elevated up to 788 IU/L (44-245 IU/
L). Electromyography (EMG) was performed and showed a few 
positive sharp waves with polyphasic myopathic motor unit action 
potentials in the right vastus medialis, tibialis anterior, and biceps 
brachii muscles, which is consistent with the active stage of gen-
eralized myopathy (Fig. 1). We planned to perform a muscle biopsy 
for confirmation, but he refused to have a muscle biopsy. The 
serum CK level was elevated up to 728 IU/L, 4 months prior to this 
visit. At that time, he felt general weakness, but he did not stop 
taking telbivudine. Because most of telbivudine-related CK eleva-
tions were transient and increased CK levels decreased to normal 
range without any interruption. However, his symptoms persisted 
and CK elevation was also shown. Thus, he was diagnosed him 
with telbivudine-induced myopathy based on the clinical clues and 
EMG findings and decided to change the anti-viral agent to 0.5 
mg entecavir once daily. He revisited our clinic at one month after 
telbivudine withdrawal, and his clinical symptoms subsequently 
improved to the extent that he was able to climb stairs easily. The 
serum CK level was also decreased to 326 IU/L.
Case 2
A 25-year-old man who received telbivudine therapy for chronic 
hepatitis B presented with progressive generalized weakness and 
difficulty exercising. He was diagnosed with CHB 4 years ago, and 
took lamivudine at first, but he changed to combination therapy 
of 600 mg of telbivudine once daily for 13 months and 10 mg of 
adefovir once to control HBV activation and lamivudine resistance. 
At 12 months after starting treatment, the HBV DNA level de-
creased to the undetectable range, and the elevated serum AST 
and ALT levels also decreased along with viral stabilization. How-
ever, the patient began to suffer from generalized weakness and 
difficult exercising since about 2 years after the treatment. He did 
not have dysphagia, cramps, or sensory symptoms and did not ex-
hibit motor weakness. Laboratory analyses showed AST of 54 IU/
L, ALT of 57 IU/L, total bilirubin of 0.4 mg/dL, BUN of 13.4 mg/dL, 
and serum creatinine of 1.15 mg/dL, and serum CK was elevated 
up to 2,992 IU/L. In this case, we did not conduct EMG. These 
two patients were siblings and they started taking telbivudine at 
the same time. Also, his symptoms were similar to those of his 
brother. His brother was diagnosed telbivudine-induced myopa-
thy in advance. He visited the department of neurology and was 
Figure 1. Electromyographic findings of one of the patients (case 1). 
Mild, sharp, positive waves with small, brief amplitudes, and polyphasic 
myopathic motor unit action potentials with full interference patterns 
were recorded in the right biceps brachii muscles.
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diagnosed with toxic myopathy. For these reasons, we empirically 
diagnosed this patient with telbivudine-induced myopathy and 
decided to switch telbivudine to entecavir, so he received combi-
nation therapy with 0.5 mg of entecavir and 10 mg of adefovir. 
Two months after telbivudine withdrawal, he revisited our clinic 
and his laboratory test showed decreased CK level to the normal 
range of 157 IU/L. Also, his clinical symptoms of muscle weakness 
have improved. 
DISCUSSION
Telbivudine, a new synthetic analogue of thymidine, is phosh-
porylated by host cellular kinases to telbivudine-5’-triphosphate, 
which has a half-life of 14 hours in vivo.10 Telbivudine-5’-triphos-
phate is then incorporated into HBV DNA by HBV polymerase, 
competing with thymidine-5’-triphosphate, the natural substrate.10 
Once inserted, telbivudine-5’-triphosphate causes DNA chain ter-
mination, thereby inhibiting HBV replication.14,15 
Since telbivudine was approved for the treatment of CHB, there 
have been a few studies11,12,14,16,17 reporting telbivudine-related 
adverse reactions. In the GLOBE trial, grade 3 or 4 elevation in 
CK levels was observed in 88 (12.9%) of 680 patients on the 
telbivudine arm.10,18 Myopathy, characterized by muscle pain, 
weakness, and elevated CK levels, was reported in two patients, 
which resolved after telbivudine was discontinued.12,17 Preliminary 
data in the GLOBE trial11 found that 9 (1.4%) patients had new 
onset of grade 3 or 4 CK elevations and 9 (1.4%) had myalgia or 
myositis between 104 and 156 weeks.11,15,19 The safety profile of 
telbivudine over three years was similar to that reported at two 
years in the GLOBE trial; most adverse effects were mild and tran-
sient in nature and no new safety signals were observed.20 The 
most common treatment-related adverse effects were elevated CK 
levels (7.5%), headache (3.6%), fatigue (2.9%), nausea (2.9%), 
diarrhea (2.2%), and nasopharyngitis (1.9%).20 Myalgia, myositis 
and muscular weakness were reported in 22 (5.3%), 2 (0.5%) 
and 2 (0.5%) patients, respectively.20 Xue-song Zhang et al. retro-
spectively reviewed five patients,18 and reported adverse reactions 
of telbivudine. Myalgia accompanied by general weakness, was 
the most common adverse reaction and the limb skeletal muscles 
were affected most frequently.17,19 There were four cases with 
peripheral nervous system involvement, represented by numbness 
and neuralgia, and one case with cardiac arrhythmia.12,18 While the 
adverse reactions of the cardiac and nervous systems persisted for 
a long time after discontinuation of telbivudine, myalgia resolved 
in a short period of time.12 Although several authors have reported 
regarding telbivudine-related adverse reactions from Western and 
Eastern countries,10-12,16 there have been no reports in Korea, espe-
cially regarding telbivudine-related adverse reactions, such as CK 
elevation or myopathy. To the best of our knowledge, this is the 
first report in Korea regarding telbivudine-related myopathy. 
In these cases, the interesting point was that the two patients 
were siblings. The two sibling patients had started treatment for 
CHB around the same time and had been taking telbivudine for 9 
months and 13 months, respectively. The duration of telbivudine 
treatment was too short compared to the other reports. This is the 
reason that there may be a genetic problem to telbivudine-induced 
myopathy. When they had myalgia symptoms, both of their CK 
levels were elevated to 788 IU/L and 2,992 IU/L. According to the 
data from our institute, 20 (7.7%) of 259 patients who have been 
prescribed with telbivudine showed evidence of serum CK eleva-
tion during their follow-up periods. However, in most of them, 
serum CK elevation did not accompany with symptoms such as 
muscle weakness and myopathy. Furthermore, their increased CK 
levels decreased to the normal range without any interruption. Al-
though we were not able to make clear the process of telbivudine-
induced myopathy because the patients did not want to have a 
muscle biopsy and DNA study, their elevated CK levels decreased 
only after telbivudine withdrawal. In addition, their symptoms 
were also improved after discontinuing telbivudine treatment. 
Therefore, we were able to conclude that myopathy in these two 
patients might be related to telbivudine.
In Korea, CK elevation and myopathy were reported in many 
cases of long-term clevudine use.21-25 Some investigators have 
reported that these adverse reactions are related to mitochondrial 
toxicity because most NAs including telbivudine as well as clevu-
dine commonly induce mitochondrial damage by inhibiting mito-
chondrial DNA polymerase.18,26 Another study has suggested that 
the mechanism is associated with cell energy metabolism.14,18,19 
Mitochondria are involved in the production of energy.18 They 
contain many important proteins, enzymes, and carriers that par-
ticipate in energy transduction. Deficiency in any of these leads to 
a poor substrate supply for oxidative phosphorylation and eventu-
ally to inadequate manufacture of the energy molecule ATP, which 
in turn causes mitochondrial disease.18 As a competitive substrate 
of natural thymidine, telbivudine is phosphorylated by host mi-
tochondrial thymidine kinases to telbivudine-5’-triphosphate and 
thymidine kinases are extensively exhausted.18 As a result, the 
normal energy transduction process is disturbed. Moreover, in the 
process of phosphorylation, high levels of phosphates are cap-
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tured, which leads directly to exhaustion of ATP, resulting in poor 
energy supply.18 Nevertheless, at present, the biological mecha-
nism of telbivudine-related CK elevations and myopathy is not yet 
clear. In this report, it was highly suspected that there might be 
a genetic problem related to this cell energy metabolism because 
the two patients were sibilings. Further investigation for the ge-
netic polymorphism associated with drug clearance in these two 
patients would be helpful to figure out the pharmaco-dynamic 
relevance.
In conclusion, here we report two uncommon cases of telbivu-
dine-induced serum CK elevation accompanied with myopathy in 
CHB patients. Even though there have been no cases of telbivu-
dine-induced myopathy in Korea, physicians should take into con-
sideration the possibility of the relationship with telbivudine as in 
the cases of clevudine if they were met with such an adverse reac-
tion in their clinical practice. In addition, further closer monitoring 
is recommended for the evaluation of CK elevation or myopathy in 
patients who were treated with telbivudine.
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